BRAF and cancer: BRAF MT tumors were significantly more prevalent in the MSI-H population, constituting 62.8% of this subgroup (p<0.001), while All-WT, KRAS MT, and NRAS MT cancer specimens were less frequent, accounting for 21.1%, 15.4%, and 0.7%, respectively (Figure 2, p<0.001 for each).